Lanfranchi G A, Bazzocchi G, Campieri M, Brignola C, Fois F, Imbimbo B P
Istituto di Clinica Medica e Gastroenterologia, Università di Bologna, Italy.
Eur J Clin Pharmacol. 1988;33(6):571-5. doi: 10.1007/BF00542489.
Cimetropium bromide is an antimuscarinic compound with antispasmodic properties. Its effect on meal-stimulated sigmoid motor activity in 30 patients with the irritable bowel syndrome, mainly with pain and constipation, has been evaluated. The mechanical activity of the sigmoid colon was recorded with a probe with three open-tipped tubes ending 45, 30, and 15 cm from the anal margin. After a recording period of 60 min, 5 mg cimetropium bromide or saline was given i.v., according to a randomized, double-blind design 5 min before a 1000 calorie meal, and motility was then recorded for 2 h. The meal caused a significant increase in motor activity for 90 min in the saline-treated group. Cimetropium bromide abolished the peak of motor activity 10-20 min after the meal and significantly inhibited postprandial colonic motility for at least 2 h (p less than 0.01). This effect provides a rationale for the use of cimetropium bromide in treatment of the irritable bowel syndrome.
溴化西托溴铵是一种具有解痉特性的抗毒蕈碱化合物。已评估了其对30例主要表现为疼痛和便秘的肠易激综合征患者进食刺激后乙状结肠运动活性的影响。使用一根带有三根开口尖端导管的探头记录乙状结肠的机械活动,导管末端距离肛门边缘分别为45厘米、30厘米和15厘米。在记录60分钟后,按照随机、双盲设计,在进食1000卡路里餐食前5分钟静脉注射5毫克溴化西托溴铵或生理盐水,然后记录2小时的运动活性。在生理盐水治疗组中,进食导致运动活性在90分钟内显著增加。溴化西托溴铵在进食后10 - 20分钟消除了运动活性峰值,并显著抑制餐后结肠运动至少2小时(p < 0.01)。这一效应为溴化西托溴铵用于治疗肠易激综合征提供了理论依据。